Q4 2025 Kiniksa Pharmaceuticals International PLC Earnings Call Transcript
Key Points
- ARCALYST product revenue grew 65% year-over-year to $202.1 million in the fourth quarter and 62% to $677.6 million for the full year 2025.
- Kiniksa Pharmaceuticals International PLC maintains a strong financial position with $414.1 million in cash at the end of 2025.
- The company has successfully initiated a Phase 2, Phase 3 clinical trial for KPL-387 in recurrent pericarditis, with data expected in the second half of 2026.
- ARCALYST has been profitable since the fourth quarter of 2021, allowing for strategic investments in sales and marketing.
- The company is expanding its reach into the recurrent pericarditis market, with more than 4,150 prescribers having written prescriptions for ARCALYST by the end of 2025.
- Operating expenses increased year-over-year due to higher costs associated with ARCALYST growth and increased collaboration expenses.
- The company faces seasonal headwinds in Q1 due to payer plan changes and co-pay resets, which could impact revenue.
- There is uncertainty regarding the peak penetration of ARCALYST in the recurrent pericarditis market.
- The development of KPL-387 and KPL-1161 is still in early stages, with potential market entry years away.
- The company has not provided specific guidance on the initiation of the Phase 3 study for KPL-387, leaving some uncertainty about the timeline.
Thank you for standing by. Welcome to the Kiniksa Pharmaceuticals fourth-quarter and full-year 2025 earnings conference call. (Operator Instructions) As a reminder, today's program is being recorded.
And now I'd like to introduce your host for today's program, Jonathan Kirshenbaum, Investor Relations. Please go ahead, sir.
Thank you, operator. Good morning, everyone, and thank you for joining Kiniksa's call to discuss our fourth-quarter and full-year 2025 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the Investors section.
As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. From there, Ross Moat, our Chief Operating Officer, will discuss our IL-1 inhibition franchise and provide an update on ARCALYST commercial execution.
Then, Kiniksa's Chief Financial Officer, Mark Ragosa, will review our fourth-quarter and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
